14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC, Meza-Montenegro MM, Peña R, Peña EM, Salazar-Martínez E, Correa P, Martínez ME, Valdivieso M, Goodman GE, Crowley JJ, Baker LH (2011) Lancet 378: 507-14 Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, Daugherty JR, Kaltenbach LA, Stein CM (2010) Ann Intern Med 152: 337-45 Proton pump inhibitor therapy improves symptoms in postnasal drainage. Vaezi MF, Hagaman DD, Slaughter JC, Tanner SB, Duncavage JA, Allocco CT, Sparkman C, Clement LE, Wasden CM, Wirth D, Goutte M, McCafferty BA, Lanza DC (2010) Gastroenterology 139: 1887-1893.e1; quiz e11 Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Ray WA, Chung CP, Stein CM, Smalley WE, Hall K, Arbogast PG, Griffin MR (2007) Gastroenterology 133: 790-8 The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. McGowan CC, Cover TL, Blaser MJ (1994) Gastroenterology 107: 738-43 The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. McGowan CC, Cover TL, Blaser MJ (1994) Gastroenterology 107: 1573-8 Control of acid and duodenogastroesophageal reflux (DGER) in patients with Barrett's esophagus. Yachimski P, Maqbool S, Bhat YM, Richter JE, Falk GW, Vaezi MF (2015) Am J Gastroenterol 110: 1143-8 High economic burden of caring for patients with suspected extraesophageal reflux. Francis DO, Rymer JA, Slaughter JC, Choksi Y, Jiramongkolchai P, Ogbeide E, Tran C, Goutte M, Garrett CG, Hagaman D, Vaezi MF (2013) Am J Gastroenterol 108: 905-11 Caution about overinterpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease. Slaughter JC, Goutte M, Rymer JA, Oranu AC, Schneider JA, Garrett CG, Hagaman D, Vaezi MF (2011) Clin Gastroenterol Hepatol 9: 868-74 CYP2C19 Phenotype and Risk of Proton Pump Inhibitor-Associated Infections. Bernal CJ, Aka I, Carroll RJ, Coco JR, Lima JJ, Acra SA, Roden DM, Van Driest SL (2019) Pediatrics 144: Gastric graft-versus-host disease revisited: does proton pump inhibitor therapy affect endoscopic gastric biopsy interpretation? Welch DC, Wirth PS, Goldenring JR, Ness E, Jagasia M, Washington K (2006) Am J Surg Pathol 30: 444-9 Extra-esophageal manifestations of gastroesophageal reflux disease: diagnosis and treatment. Hom C, Vaezi MF (2013) Drugs 73: 1281-95 Randomised clinical trial: high-dose acid suppression for chronic cough - a double-blind, placebo-controlled study. Shaheen NJ, Crockett SD, Bright SD, Madanick RD, Buckmire R, Couch M, Dellon ES, Galanko JA, Sharpless G, Morgan DR, Spacek MB, Heidt-Davis P, Henke D (2011) Aliment Pharmacol Ther 33: 225-34 Therapeutic strategies for laryngeal manifestations of gastroesophageal reflux disease. Yuksel ES, Vaezi MF (2013) J Clin Gastroenterol 47: 195-204 Approach to the patient with presumed extraoesophageal GERD. Ates F, Vaezi MF (2013) Best Pract Res Clin Gastroenterol 27: 415-31 Extra-esophageal gastroesophageal reflux disease and asthma: understanding this interplay. Naik RD, Vaezi MF (2015) Expert Rev Gastroenterol Hepatol 9: 969-82 The role of impedance monitoring in patients with extraesophageal symptoms. Kavitt RT, Yuksel ES, Slaughter JC, Garrett CG, Hagaman D, Higginbotham T, Vaezi MF (2013) Laryngoscope 123: 2463-8 Randomized controlled trial comparing esophageal dilation to no dilation among adults with esophageal eosinophilia and dysphagia. Kavitt RT, Ates F, Slaughter JC, Higginbotham T, Shepherd BD, Sumner EL, Vaezi MF (2016) Dis Esophagus 29: 983-991
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.